-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2025-521511-40-00
10
2025-11-18
metastatic non-small cell lung cancer
-
2024-519654-37-00
10
2025-11-07
Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-520264-33-00
5
2025-10-07
Locoregionally recurrent head and neck squamous cell carcinoma (HNSCC)
-
2023-509861-19-01
4
2025-09-30
High-grade B-cell lymphoma (HGBL)
-
2025-520519-14-00
5
2025-09-03
Atherosclerotic Cardiovascular Disease
-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-515894-80-00
5
2025-07-01
Severe Alpha-1 Antitrypsin Deficiency (AATD)
-
2024-517423-40-00
5
2025-06-23
Metastatic Castration-Resistant Prostate Cancer
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-512302-25-00
5
2025-06-06
Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
-
2024-517335-46-00
4
2025-06-05
Bladder cancer
-
2024-515526-89-00
4
2025-05-16
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2023-506327-29-00
5
2025-05-14
Non-Small Cell Lung Cancer
-
2024-512679-11-00
5
2025-04-25
unborn baby with developmental disorder of the left side of the heart
-
2024-516367-80-00
4
2025-04-24
resectable and borderline resectable stage IIIA/B NSCLC
-
2024-511935-86-00
4
2024-12-18
Locally advanced or metastatic synovial sarcoma ICD-O3, 9040/3, 9041/3
-
2023-508418-40-00
9
2024-12-16
Head and Neck Squamous Cell Carcinoma
-
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
-
2023-504925-38-00
4
2024-12-10
patients with hormone receptor (HR)-positive, HER2-negative locally ad
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma